Senior Director CMC, Islet Cell Therapy

Sigilon Therapeutics is a multidisciplinary biotechnology company which specializes in creating immune privileged products to address unmet clinical needs. Our mission at Sigilon Therapeutics is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases. We are based in Kendall Square in Cambridge, MA, and funded by Flagship Pioneering. Please send your application via email to careers@sigilon.com

Sigilon Therapeutics is searching for an energized candidate to lead a new team focused on CMC and manufacturing a novel therapeutic product for diabetes utilizing Sigilon’s Afibromer™ technology combined with leading edge pancreatic islet cell technology.

Responsibilities

Sigilon Therapeutics is searching for an energized candidate to lead a new team focused on CMC and manufacturing a novel therapeutic product for diabetes utilizing Sigilon’s Afibromer™ technology combined with leading edge pancreatic islet cell technology. This individual would have primary responsibility for all aspects of CMC and manufacturing including: process development, analytical development, and CMC. Initial emphasis will be on partnering with the research team to create a protocol that can be transferred to a CMO. Management of the CMO relationship will be a key responsibility.  The team will have full access to all of Sigilon’s cell biology and encapsulation chemistry expertise along with substantial designated funds to enable a rapid pursuit of a very robust and competitive program.

KEY RESPONSIBILITIES

Requirements